Zero Point Five Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Zero Point Five Therapeutics, Inc. - overview
Established
2018
Location
Baltimore, MD, US
Primary Industry
Biotechnology
About
Based in Maryland, US and founded in 2018, Zero point five therapeutics operates as a biotechnology company that focuses on developing ZP5-9676, a drug used to treat neglected tropical diseases. The company was founded by its CEO Joseph Amprey and CSO Helen Pentikis. In April 2025, Zero Point Five Therapeutics, Inc. raised USD 4.
30 million in series C funding from returning investor TEDCO and other unspecified investors. The biotechnology company develops a drug to fight against diseases caused by whipworms, tapeworms, and hookworms. It is a single-dose therapy that treats soil-transmitted helminths which include Necator americanus, roundworm, whipworm, etc. The company will use the April 2025 funding to support its research and development efforts.
Current Investors
Portfolia, TEDCO
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.zeropointfivetherapeutics.com
Verticals
HealthTech
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.